Exact sciences corporation stock.

On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation …

Exact sciences corporation stock. Things To Know About Exact sciences corporation stock.

Check out my recommendation on EXAS stock. Exact Sciences' successful BLUE-C study and potential FDA approval for the upgraded test may drive revenues. ... 2023 8:00 AM ET Exact Sciences ...Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...Achieving some impressive results. Exact Sciences has already done well in growing its business. Sales of $1.8 billion in 2021 were double what the company generated in 2019 ($876 million).Nov 30, 2023 · Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ...Nov 30, 2022 · Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price-earnings ratio. Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% net profit margin. Year-over-year quarterly sales growth most recently was 20.1%.

View live Exact Sciences Corporation chart to track its stock's price action. Find market predictions, EXAS financials and market news.

Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to …Exact Sciences Corp (NASDAQ:EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the consensus of $599.03 million.According to 15 stock analysts, the average 12-month stock price forecast for Exact Sciences stock is $92.07, which predicts an increase of 39.52%. The lowest target is $73 and the highest is $130. On average, analysts rate Exact Sciences stock as a strong buy.EXACT Sciences Corporation share price live 65.59, this page displays NASDAQ EXAS stock exchange data. ... Monitor the latest movements within the EXACT Sciences Corporation real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit …Exact Sciences Corporation Common Stock (EXAS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients CI Nov. 29: Transcript : Exact Sciences Corporation Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:30 PM

Analyst Report: Exact Sciences Corporation Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and ...

Exact Sciences Corporation. 01 Aug, 2023, 16:05 ET. Reports record results, generates positive free cash flow, raises full-year guidance. Second-quarter 2023 highlights. Total second quarter ...Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ... Get the latest news and real-time alerts from Exact Sciences Corporation (EXAS) stock at Seeking Alpha. ... EXAS Exact Sciences Corporation. Latest News. Follow $65.82-0.17 (-0.26%) ...Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to …Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ...Exact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | Nasdaq

In my May 2022 article on Exact Sciences Corporation (NASDAQ:EXAS), titled "Exact Sciences Won't Likely Escape Consolidation in the Industry," I pointed out the need for the company to turn its ...5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024. We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal ...Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more. Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 8.31% so far this month. During the month of March, Exact Sciences Corp’s stock price has reached a high of $67.82 and a low of $60.85. Over the last year, Exact Sciences Corp has hit prices as high as $76.94 and as low as $29.27. Year to date, Exact ...Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ... See Exact Sciences Corporation (EXAS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Buy candidate since Nov 17, 2023 Loss -1.39% PDF. The EXACT Sciences Corporation stock price gained 0.368% on the last trading day (Wednesday, 22nd Nov 2023), rising from $65.14 to $65.38. During the last trading day the stock fluctuated 3.02% from a day low at $64.84 to a day high of $66.80. The price has been going up and down for this period ...

Shares Held % O/S Share Change Filing Date; The Vanguard Group, Inc. 17,175: 9.52: 164: 06/30/2023: JPMorgan Investment Management, Inc. 12,307: 6.82: 878: 06/30/2023 Get EXACT Sciences Corporation (EXAS) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial ...Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See …Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA …Adjusted EBITDA for the three and six months ended June 30, 2021 has been updated accordingly for comparative purposes. Of the $64.5 million and $60.8 million incurred for the three months ended June 30, 2022 and 2021, $56.4 million and $53.9 million is related to stock-based compensation, respectively, and $8.1 million and $6.9 million is ...On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...

Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...

Determining the value of old vinyl records isn’t an exact science, according to Rare Records. A variety of factors go into determining the value of a record, and these factors are what give some vinyl albums a high value while others don’t ...

Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients CI Nov. 29: Transcript : Exact Sciences Corporation Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:30 PMExact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137! Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...MADISON, Wis., August 1, 2023 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June 30, 2023, compared to $521.6 million for the same period of 2022.MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 ...26-Feb-2016 ... 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, ...Feb 3, 2023 · Achieving some impressive results. Exact Sciences has already done well in growing its business. Sales of $1.8 billion in 2021 were double what the company generated in 2019 ($876 million). 22-Feb-2022 ... MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...

MADISON - Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research (AACR) Annual Meeting 2023, April 14-19, in …11-Feb-2020 ... Exact Sciences Announces Fourth-Quarter 2019 Results ; Net income (loss) per share—basic. $. 0.56 ; Net income (loss) per share—diluted. $. 0.54.Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3. Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter.Find the latest Exact Sciences Corporation (EXK.F) stock quote, history, news and other vital information to help you with your stock trading and investing.Instagram:https://instagram. ivw holdingsveng stock forecast 2025where can i get free cryptointeractive brokers options paper trading On December 30, 2022, the Board of Directors (the Board") of Exact Sciences Corporation (the Company") expanded the size of the Board from 9 to 10 members and elected D. Scott Coward to serve as a Class II member of the Board …On December 30, 2022, the Board of Directors (the Board") of Exact Sciences Corporation (the Company") expanded the size of the Board from 9 to 10 members and elected D. Scott Coward to serve as a Class II member of the Board … stock dividend yieldcommodity futures brokers Exact Sciences Corp (NASDAQ:EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the consensus of $599.03 million. how many stocks should i have in my portfolio 09-Oct-2023 ... MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests ...Aug 2, 2022 · Under the terms of the asset purchase agreement, mdxhealth acquired the Oncotype DX GPS prostate cancer business of Exact Sciences for an aggregate purchase price of up to $100 million, of which ... Currently, Kevin T. Conroy occupies the position of Chairman, President & Chief Executive Officer at EXACT Sciences Corp. and President & Director at Genomic Health, Inc. (a subsidiary of EXACT Sciences Corp.). He is also on the board of 8 other companies. Kevin T. Conroy previously was Partner at McDermott Will & Emery LLP, Director at ...